Annual Meeting Industry Supported Symposia Schedule

0414-annual-meeting-on-Womens-cancer

Annual Meeting > Industry Supported Symposia Schedule

Industry Supported Symposia (ISS) are unique forums for presenting educational information to SGO Annual Meeting attendees, free of charge. Symposia sessions are scheduled during lunch time, allowing participants the opportunity for education, networking and lunch.

SGO does not offer CME for any of the ISS, but does offer CME for the Lunch and Learn session. The offering of ISS does not constitute endorsement by the SGO of the information, products or services contained therein. Registration for all symposia starts 30 minutes before scheduled times noted below.

Industry Supported Symposium I
Industry Supported Symposium II
Industry Supported Symposium III
Industry Supported Symposium IV
Industry Supported Symposium V
SGO Lunch and Learn

Industry Supported Symposium I

Saturday, March 19, 2016
12:15 p.m. – 1:45 p.m. Room 6B
Addressing Current Questions and Controversies: PARP Inhibition in the Management of Ovarian Cancer and Other Gynecologic Malignancies (Part 1 of a 2-Part Series)

This CME symposium will focus on the discussion of challenging clinical situations commonly faced by community-based clinicians to create a dynamic learning format designed to both improve knowledge and assist those in attendance in becoming better and more effective caregivers.

In the months leading up to the event, Research To Practice, in collaboration with the invited faculty, consulted with a small group of practicing gynecologic oncologists who care for patients with ovarian cancer and other gynecologic malignancies to identify clinical questions and/or ambiguous data sets for which they would like to receive expert advice and feedback.

During each of the four modules at the live activity, one invited faculty member will deliver a brief presentation reviewing recent data sets, available guidelines and ongoing clinical trials that inform decision-making related to the clinical scenarios identified during the pre-meeting planning sessions.

Following each didactic presentation, an extended moderated panel discussion will be introduced to obtain the perspectives of the other faculty members on these topics. To maintain audience interest and relevance, clinician attendees will have the opportunity to participate in a pre-meeting survey utilizing networked handheld polling devices which will include general and case-based questions related to the topics that will be discussed. The results will be displayed throughout the event to foster additional conversation.

Moderator:
Neil Love, MD, Research to Practice, Miami, FL

Faculty: 
Ursula A. Matulonis, MD, Dana-Farber Cancer Institute, Boston, MA
Kathleen Moore, MD, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Amit M. Oza, MD, Princess Margaret Cancer Centre; Toronto , ON, Canada
Elizabeth M. Swisher, MD, University of Washington School of Medicine, Seattle, WA

For more information or to register, visit: http://www.researchtopractice.com/Meetings/GynOnc2016 

REGISTER HERE

This activity is supported by educational grants from AbbVie, Inc., AstraZeneca Pharmaceuticals LP, Clovis Oncology and Myriad Genetic Laboratories Inc. CME provided by Research to Practice.

Industry Supported Symposium II

Saturday, March 19, 2016
12:15 p.m. – 1:45 p.m. Room 6A
Expert Perspectives in PARP inhibition: Evolving Management Strategies in Ovarian Cancer

Ovarian cancer remains the leading cause of death from gynecologic cancer in the United States. Epithelial forms of ovarian cancer are characterized by their heterogeneity and divided according to histologic subtype. The identification of distinct molecular pathways among certain subtypes of these tumors has fueled enthusiasm concerning the development of targeted therapies for ovarian cancer. Indeed, emerging evidence in this therapeutic space has created the need for educational programming that allows experts to provide their perspectives to translate clinical trial results so they can be practically applied to practice.

For this not-to-be-missed symposium, we are bringing together a panel of internationally recognized experts in the management of ovarian cancer to discuss how we can optimize treatment for these patients. Faculty will cover key topics key to evolving treatment paradigms in ovarian cancer, including:

  • Mechanism of action among PARP inhibitors
  • The use of genetic testing
  • Drug resistance mechanisms
  • Evidence on the use of single agent PARP inhibition
  • Combination approaches; and
  • A look to the not-so-distant future of ovarian cancer treatment

Program Chair: 
Maurie Markman, MD, Cancer Treatment Centers of America, Philadelphia, PA

Faculty:
Michael Birrer, MD, Massachusetts General Hospital, Boston, MA;
Joyce Liu, MD, MPH, Dana-Farber Cancer Institute, Boston, MA;
James Tate Thigpen, MD, University of Mississippi Medical Center, Jackson, MS

To register, visit URL: http://www.gotoper.com/conferences/SGO16/meetings/Expert-Perspectives-in-PARP-Inhibition-Evolving-Management-Strategies-in-Ovarian-Cancer 

REGISTER HERE

This activity is supported by an educational grant from Clovis Oncology, Foundation Medicine, Inc., and Myriad Genetics. CME provided by Physicians’ Education Resource.

Industry Supported Symposium III

Sunday, March 20, 2016
12:30 p.m. – 2:00 p.m. Room 6B
Addressing Current Questions and Controversies: Emerging Treatment Strategies and Novel Approaches in Gynecologic Cancers (Part 2 of a 2-Part Series)

This CME symposium will focus on the discussion of challenging clinical situations commonly faced by community-based clinicians to create a dynamic learning format designed to both improve knowledge and assist those in attendance in becoming better and more effective caregivers.

In the months leading up to the event, Research To Practice, in collaboration with the invited faculty, consulted with a small group of practicing gynecologic oncologists who care for patients with ovarian cancer and other gynecologic malignancies to identify clinical questions and/or ambiguous data sets for which they would like to receive expert advice and feedback.

During each of the four modules at the live activity, one invited faculty member will deliver a brief presentation reviewing recent data sets, available guidelines and ongoing clinical trials that inform decision-making related to the clinical scenarios identified during the pre-meeting planning sessions.

Following each didactic presentation, an extended moderated panel discussion will be introduced to obtain the perspectives of the other faculty members on these topics. To maintain audience interest and relevance, clinician attendees will have the opportunity to participate in a pre-meeting survey utilizing networked handheld polling devices which will include general and case-based questions related to the topics that will be discussed. The results will be displayed throughout the event to foster additional conversation.

Moderator:
Neil Love, MD, Research to Practice, Miami, FL

Faculty:
Michael Birrer, MD, Massachusetts General Hospital, Boston, MA
Thomas J. Herzog, MD, University of Cincinnati, Cincinnati, OH
Bradley J. Monk, MD, Creighton University School of Medicine, St. Josephs Hospital and Medical Center, Phoenix, AZ;
Angeles Alvarez Secord, MD, Duke University Medical Center, Durham, NC

For more information or to register, visit: http://www.researchtopractice.com/Meetings/GynOnc2016

REGISTER HERE

This activity is supported by educational grants from Genentech BioOncology and ImmunoGen Inc. CME provided by Research to Practice.

Industry Supported Symposium IV

Sunday, March 20, 2016
12:30 p.m. – 2:00 p.m. Room 6A
Pap+HPV Together: Comprehensive Care in Cervical Cancer Screening

Join us for an expert panel review of the latest developments in cervical cancer, safeguarding women’s health today and in the future.

This activity is supported by an educational grant from Hologic.

Industry Supported Symposium V

Monday, March 21, 2016
12:45 p.m. – 2:15 p.m. Room 6A
Advances in Anti-VEGF Therapy: From Discovery to Treatment of Gynecologic Malignancies

Our distinguished panel will provide a historical perspective of anti-angiogenesis and hold a case-based discussion on the role of anti-VEGF therapy in the treatment of platinum-resistant ovarian and advanced cervical cancers.

Moderator:
Maurie Markman, MD, President, Medicine & Sciences, Cancer Treatment Centers of America, Philadelphia, PA

Faculty:
Bradley J Monk, MD, Creighton University School of Medicine, St. Joseph’s Hospital and Medical Center,Phoeniz, AZ
Krishnansu S. Tewari, MD, Professor and Director of Research, Division of Gynecologic Oncology, University of California, Irvine Medical Center, Irvine, CA

To register, visit www.AdvancesInAntiVEGF.com 

REGISTER HERE

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

SGO Lunch and Learn

Monday, March 21, 2016
12:45 p.m. – 2:15 p.m. Room 6B
Evolution and Revolution of PARP Targeting in Gynecologic Malignancies

REGISTER HERE

Course Director:
Ursula A. Matulonis, MD, Dana Farber Cancer Institute, Boston, MA

Faculty:
Joyce F. Liu, MD, Dana-Farber Cancer Institute, Boston, MA
Shannon M. Westin, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

What have we learned from the use of PARP inhibitor therapies and other targeted therapies in the treatment of ovarian cancer and maintenance therapy in progression-free survival in women with recurrent platinum-sensitive ovarian cancer? Explore novel therapeutic options combining PARP inhibitors with anti-angiogenic agents, immunotherapies, and other treatment modalities. This Lunch and Learn will explore the concept of improving upon PARP therapies in patients with known vulnerabilities in order to best leverage PARP and other targeted therapies in combination. This activity is supported by an educational grant from AstraZeneca.

This Lunch and Learn session will allow attendees the opportunity to enjoy lunch, networking, and high-level education designed and accredited by SGO.

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP. CME is provided by SGO.